Internal Reference Number: FOI_8139
Date Request Received: 06/09/2024 00:00:00
Date Request Replied To: 01/10/2024 00:00:00
This response was sent via: By Email
Request Summary: Usage of biologic and biosimilar products
Request Category: Media
| Question Number 1: Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Baricitinib [Olumiant] • Bimekizumab [Bimzelx] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Filgotinib [Jyseleca] • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Rituximab [MabThera] • Rituximab Biosimilars • Sarilumab [Kevzara] • Secukinumab [Cosentyx] • Tocilizumab [Ro Actemra] • Tocilizumab Biosimilars • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara] • Ustekinumab Biosimilar | |
| Answer To Question 1: 0 patients | |
| Question Number 2: Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs. • Adalimumab [Humira] • Adalimumab Biosimilars • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Golimumab [Simponi] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Secukinumab [Cosentyx] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] | |
| Answer To Question 2: 0 patients | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
